BACKGROUND: Human parechoviruses (HPeVs) are RNA viruses associated with mild gastrointestinal and respiratory infections in children, but may also cause neonatal sepsis and CNS infections in infants. While the prevalence of HPeVs is known mostly among hospitalized populations, the knowledge of HPeV seroprevalence in the general population is poor. OBJECTIVES: The aim of this study was to identify and compare the HPeV1-6 seroprevalence in Finnish and Dutch populations. STUDY DESIGN: A type specific microneutralization assay was set up for detecting neutralizing antibodies (nABs) against HPeV types 1-6. Altogether 616 serum samples from Finnish and Dutch population were analyzed for antibodies against HPeVs. The samples were collected from Finnish children aged 1, 5 or 10 years, Finnish adults, 0- to 5-year-old Dutch children, Dutch women of childbearing age and Dutch HIV-positive men. RESULTS: In both adult populations, seropositivity was high against HPeV1 (99% in Finnish and 92% in Dutch samples) and HPeV2 (86% and 95%). Against HPeV4, the seropositivity was similar (62% and 60%). In Dutch adults, nABs against HPeV5 and 6 (75% and 74%) were detected more often than in Finnish adults (35% and 57%, respectively). In contrast, seropositivity against HPeV3 was as low as 13% in the Finnish and 10% in the Dutch adults. The seroprevalence of all HPeV types increased with age. CONCLUSIONS: The seroprevalence of HPeVs is high in Finnish and Dutch populations and HPeV type 2 and types 4-6 are significantly more prevalent compared to earlier reports. The seroprevalence of antibodies observed against HPeV3 was low.
BACKGROUND: Human parechoviruses (HPeVs) are RNA viruses associated with mild gastrointestinal and respiratory infections in children, but may also cause neonatal sepsis and CNS infections in infants. While the prevalence of HPeVs is known mostly among hospitalized populations, the knowledge of HPeV seroprevalence in the general population is poor. OBJECTIVES: The aim of this study was to identify and compare the HPeV1-6 seroprevalence in Finnish and Dutch populations. STUDY DESIGN: A type specific microneutralization assay was set up for detecting neutralizing antibodies (nABs) against HPeV types 1-6. Altogether 616 serum samples from Finnish and Dutch population were analyzed for antibodies against HPeVs. The samples were collected from Finnish children aged 1, 5 or 10 years, Finnish adults, 0- to 5-year-old Dutch children, Dutch women of childbearing age and Dutch HIV-positive men. RESULTS: In both adult populations, seropositivity was high against HPeV1 (99% in Finnish and 92% in Dutch samples) and HPeV2 (86% and 95%). Against HPeV4, the seropositivity was similar (62% and 60%). In Dutch adults, nABs against HPeV5 and 6 (75% and 74%) were detected more often than in Finnish adults (35% and 57%, respectively). In contrast, seropositivity against HPeV3 was as low as 13% in the Finnish and 10% in the Dutch adults. The seroprevalence of all HPeV types increased with age. CONCLUSIONS: The seroprevalence of HPeVs is high in Finnish and Dutch populations and HPeV type 2 and types 4-6 are significantly more prevalent compared to earlier reports. The seroprevalence of antibodies observed against HPeV3 was low.
Authors: B M Westerhuis; K S M Benschop; G Koen; Y B Claassen; K Wagner; A Q Bakker; K C Wolthers; T Beaumont Journal: J Virol Date: 2015-05-06 Impact factor: 5.103
Authors: Herbert Kurz; Ruth Prammer; Wolfgang Bock; Robert Ollerieth; Günther Bernert; Karl Zwiauer; Judith H Aberle; Stephan W Aberle; Tamas Fazekas; Wolfgang Holter Journal: Eur J Pediatr Date: 2015-06-25 Impact factor: 3.860
Authors: Eveliina Karelehto; Sabine van der Sanden; James A Geraets; Aušra Domanska; Lonneke van der Linden; Dionne Hoogendoorn; Gerrit Koen; Hetty van Eijk; Shabih Shakeel; Tim Beaumont; Menno de Jong; Dasja Pajkrt; Sarah J Butcher; Katja C Wolthers Journal: Sci Rep Date: 2017-09-21 Impact factor: 4.379
Authors: Silke Vollbach; Andreas Müller; Jan Felix Drexler; Arne Simon; Christian Drosten; Anna Maria Eis-Hübinger; Marcus Panning Journal: Virol J Date: 2015-11-25 Impact factor: 4.099
Authors: Eveliina Karelehto; Joanne G Wildenbeest; Kimberley S M Benschop; Gerrit Koen; Sjoerd Rebers; Saskia Bouma-de Jongh; Brenda M Westerhuis; Menno D de Jong; Dasja Pajkrt; Katja C Wolthers Journal: Pediatr Infect Dis J Date: 2018-12 Impact factor: 2.129